



Which Antimicrobial Peptides Have An Inhibitory Effect On Tuberculosis?

Bahar Sadegh Ehdai¹, Mehdi Shabani¹ and Masoud Keikha^{2,3*}

¹Department of Microbiology and Virology, Isfahan University of Medical Sciences, Iran

²Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Iran

³Department of Microbiology and Virology, Mashhad University of Medical Sciences, Iran

Abstract

Tuberculosis (TB) is caused by *Mycobacterium tuberculosis* (MTB) which is one of the top 10 causes of death worldwide. The emergence of multi-drug and extensively-drug resistant *Mycobacterium tuberculosis* strains has become as a global crisis. It's necessary to introduce the novel generation of bactericidal agents for treatment and control of drug-resistant strain. Nowadays, Antimicrobial peptides (AMPs), which are short-length, cationic and amphipathic peptides have a remarkable strategy for replacement with antibiotics in the treatment of drug-resistant infections. In this study, we discuss about numerous AMPs which have anti-tuberculosis activities against both of susceptible and drug-resistant TB strains.

Keywords: *Mycobacterium Tuberculosis*; Antimicrobial Peptide; Tuberculosis; Antibiotics; Treatment

Introduction

Tuberculosis (TB) remains as one of the important infectious diseases which is considered as the ten top of cause of people dying by WHO; According to WHO reports, there are approximately 10.7 million new TB cases in 2018, about two billion of people were contaminated by *Mycobacterium tuberculosis* which not clinical symptoms but 5-10% of there are developed to reactivation of tuberculosis [1,2]. In recent years, the advent and distribution of drug-resistant TB (DR-TB) are converted to the major concern of public health services throughout the world [2]. There are 558,000 Rifampin-resistant TB cases which 80% of these cases have MDR-TB (Multi-drug resistant which is resistant to rifampin and isoniazid) [1].

Antimicrobial peptides (AMPs) are oligopeptides which expressed in eukaryotic cells particularly human and play a key role as part of the innate immune response to infectious agents [3]. This class of macromolecules has broad-spectrum antibiotics effects which approved as novel therapeutic agents which inhibits Gram-positive, Gram-negative, fungi and enveloped virus [4]. According to the review of literature, AMPs have antimycobacterial activities which could be efficient in susceptible and MDR strains of *M. tuberculosis* [5]. In this report, we

discussed about several antimicrobial peptides which approved as a potent antibiotic for the treatment of tuberculosis.

Discussion

The current tuberculosis treatment and anti-TB resistance

The conventional therapy of tuberculosis is consisting two stages including the initial phase of rifampicin (RIF), isoniazid (INH), pyrazinamide (PYZ), and ethambutol (ETB) which are recommended daily for 2 months; followed preservative phase of RIF and INH for additional 4 months [6]. Unfortunately, the emergence and spread of Drug-resistant TB (DR-TB) particularly, Multidrug-resistant TB (MDR-TB) which is resistant to both isoniazid and rifampicin, and extensively drug-resistant TB (XDR-TB) that is MDR strains which are resistant to fluoroquinolone and one of the second-line injectable are considered as a major treat [7]. According to the review of literature, DR-TB is commonly associated with high mortality rates; it estimated that 50% of MDR-TB cases and lower than 30% of patients with XDR-TB are survived [8]. MDR-TB and XDR-TB strains are mediated by spontaneously point mutation in KatG (INH), rpoB (RIF), gyrB (fluoroquinolones) and rrs (aminoglycosides) [9]. In addition, side effect and limitation of anti-tuberculosis drugs have forced to investing in a novel generation of anti-TB drugs; nowadays, it is suggested that anti-microbial peptides are considered as potential anti-tuberculosis drugs [10,11].

Defensins

Defensins are classified as Human neutrophil peptide (HNP) and β -defencin; Human neutrophil peptide 1 (HNP-1) (peptide sequence: ACYCRIPACIAGERRYGTCTIYQGRWAFCC) is a β -sheeted cationic AMP which has antibacterial activity because of three intramolecular disulfide bonds (Figure 1) [12]. Kalita et al., have shown that MIC value of HNP1 against *M. tuberculosis* H37Rv was 2.5 μ g/ml which was higher than isoniazid (0.3 μ g/ml) and rifampicin (0.2 μ g/ml) [13]. Also, there are four types

Submitted: 19 April 2019 | **Accepted:** 10 May 2019 | **Published:** 13 May 2019

***Corresponding author:** Masoud Keikha, Department of Microbiology and Virology, Mashhad University of Medical Sciences, Mashhad, Iran, Tel: 09386836425; Email: masoud.keikha90@gmail.com

Copyright: © 2019 Ehdai BS, et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Ehdai BS, Shabani M, xKeikha M (2019) Which Antimicrobial Peptides Have An Inhibitory Effect On Tuberculosis? JSMC Biochem Mol Res 3: 4.



of β -defensin (HBD1-4); Corrales-Garcia et al., were found that HBD2 revealed sufficient bactericidal activity against *M. tuberculosis* H37Rv (1.5 M) [14].

Cathelicidins

Cathelicidins are known as one of the great AMPs which was purified from myeloid cell lines (bone marrow) for the first time; LL-37 (peptide sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLPVPTES) peptide is derived from human cationic antimicrobial protein which expressed by macrophages during entry of pathogens which significantly reduces the intracellular survival of *M. tuberculosis* [15]. Murine cathelicidin known as CRAMP (peptide sequence: GLLRKGGEKIGEKLLKIGQKIKNFFQKLVPPQEQ) has similar activity like to the human cathelicidin (Figure 1) [16]. Rivas-Santiago et al., have shown the bactericidal activity of LL-37 and mouse CRAMP against a susceptible strain of *Mtb* H37Rv and MDR strain during in vitro and in vivo studies [17].

Hepcidin

Hepcidin is a natural AMP (peptide sequence: DTHFPICIFCGCCHRSKCGMCKKT) compounds, which is expressed by the liver cells during the inflammatory process (Figure 1) [18]. Sow et al., have suggested that hepcidin could be reduced the CFUs of *Mtb*H37Rv with a concentration of 200 μ g/ml [19].

NK-lysin and granulysin

NK-lysin and granulysin are homologous cationic antimicrobial peptides which are expressed by pig and human cytotoxic lymphocytes respectively (Figure 1) [20]. NK-lysin (peptide sequence: GYFCESCRKIIQKLEDMVGPQPNEDTQTQAASQVCDK-LKILRGLCKKIMRSFLRRISWILTGKKAICVDIKICKE) has destroyed *Mtb* H37Rv during 8 days at 30 μ M [21]. Granulysin (peptide sequence: GRDYRTSLTIVQKLKMMVDKPTQRSVSNAAATRVSR) has cytolytic effects against both drug-susceptible *M. tuberculosis* and MDR-TB [22]. Also, it suggested that Granulysin has a candidate as a biomarker for diagnosis of TB [23].

Ubiquitin

Ubiquitin is naturally stored in secretory chromaffin granules and released in response to different pathogens during Pro-inflammatory process from chromaffin cells (Figure 1) [24]. Kieffer et al., identified Ub2 in lysosome which plays a key role in autophagy for *Mtb* lysis in phagolysosome [25]. Also, studies were showed that synthesized peptide Ub2 (peptide sequence: STLH-LVLRRLGG) were antibacterial activity against tubercle bacillus [21].

There are numerous class of AMPs which show bactericidal activity against both drug-susceptible strains and MDR-TB strains which classified in different class including 1) Animal AMPs (PR-39), 2) Human Immune cell-derived (LL37, mCRAMP, E2, E6, Human neutrophil peptide 1 (HNP-1), Human B-defensin (hBD2), Granulysin, granF2, G13, Lactoferrin, IDR) Human Non immune cell-derived (Ub2 (ubiquitin-derived), Hepcidin), 4) Human host defense (RNase 3, RNase 7, HCL2) , 5) Microbial AMPs (Lactacin 3147, E50-52, Lassomycin, Bacteriocins (Bcn1-Bcn5),

AS-48, NZX), 6) Synthetic AMPs (LLKKK-18, (LLKK)2, D5 (Synthetic 26-residue, amphipathic α -helical peptide), D-LAK analogs, ATRA-1A, IDR-1018), 7) Mycobacteriophage AMPs (PK34, CHAP, PlyG), lactacin 3147, E50-52 and human host defense ribonucleases (RNase) [21,26-28].

In recent years, these studies are continuously performed and novel AMPs are introduced with anti-mycobacterial effects against TB such as CXCL1/CXCL2, NZX, and AS-48 which are novel potential option for treatment of tuberculosis (Figure 1) [29-31].

CXCL1 / CXCL2

Boro et al., showed that chemokines of CXCL1 and CXCL2 were expressed during *Mtb* infection and recruit neutrophils to the site of tubercle bacillus [29].

NZX as a novel derivative of Plectasin NZX (peptide sequence: GFGCNGPWSEDDLRCRHRHCKSIKGYRGGYCAKGGFVCKCY) is derived from Plectasin in fungi which has bactericidal effects on *M. tuberculosis* both in vitro and in murine model studies [30]. Tenland et al., was found that the plectasin derivatives NZ2114 and NZX have antibacterial activities against *Mtb* (MIC concentrations were 6.3 μ M for H37Rv, 6.3 μ M and 3.2 μ M for two clinical *M. tuberculosis* isolates and 6.3 μ M for the clinical MDR isolate, respectively); they found that NZX was less toxic to human cells than LL37 [32].

AS-48

AS-48 is 70-aminoacid, an α -helical membrane-interacting peptide which is extracted from *Enterococcus faecalis* and is active against Gram-positive bacteria [31]. Aguilar-Pérez et al., have shown that the combination of AS-48 plus either lysozyme or ethambutol has anti-TB activities [33].

During present decades it is suggested that numerous cyclic peptides have antimycobacterial activities, for example, griselmocins, depsidomycin, hytramycin, brunsvicamides, pyridomycin, hirsutellide A and wollamides particularly, Wollamide B which is evaluated in several studies [34].

Wollamide B

Wollamide B is cationic cyclohexapeptide which is extracted from *Streptomyces nov.* strain MST-115088 by Khalil et al., in 2014 [35]. This compound has two uncommon residues such as D-Orn, D-Leu or four L-amino acids in the structure [35-36]. For the first time, Khalil et al., have shown that Wollamide B had IC50 of 3.1 μ M against *M. bovis*. In recent years, Asfaw et al., suggested that this compound has anti-TB effects during in vitro studies (MICs \leq 3.1 μ M against *Mtb* H37 Rv) [34,35].

The cathelicidin-like antimicrobial protein of *D. melanogaster* (dCAMP)

Jin et al., was reported the cathelicidin-like antimicrobial protein which is induced by *Drosophila* cg6568 gene during infection with *M. marinum* infection in *D. melanogaster*; this compound is cathelicidin like the activity that inhibits intracellular growth of mycobacterial species [37].




Figure 1 AMPs have ant-tuberculosis activity from A-L; A: Human neutrophil peptide, B: β -defencin, C: LL-37, D: CRAMP, E: Hecpudin, F: NK-lysin, G: granulysin, H: Ubiquitin 2, I: CXCL1, J: Plectasin, K: AS-48; respectively..

Conclusion

Antimicrobial peptides are natural oligopeptides which have the best candidate for the development of a novel natural generation of antibiotics; According to the review of the literature, there are 10 AMPs which entered clinical trials. In addition; there are several AMPs with anti-tuberculosis activity (both of susceptible and drug-resistant TB) provide the hypothesis that AMPs have the best candidates for the treatment of tuberculosis.

References

1. World Health Organization, editor. Global tuberculosis report 2018. World Health Organization; 2018.
2. Keikha M, Shabani M, Navid S, Sadegh EB, Karbalaei ZB. What is the role of "T reg Cells" in tuberculosis pathogenesis? *Indian J Tuberc*. 2018; 65: 360-362.
3. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. *Curr Eye Res*. 2005; 30: 505-515.
4. Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. Antimicrobial peptides for therapeutic applications: a review. *Molecules*. 2012; 17: 12276-12286.
5. Miyakawa Y, Ratnakar P, Rao AG, Costello ML, Mathieu-Costello O, Lehrer RI, et al. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against *Mycobacterium tuberculosis*. *Infect Immun*. 1996; 64: 926-932.
6. Kaur M, Garg T, Narang RK. A review of emerging trends in the treatment of tuberculosis. *Artif Cells Nanomed Biotechnol*. 2016; 44: 478-484.
7. Papaventsis D, Casali N, Kontsevaya I, Drobniowski F, Cirillo DM, Nikolayevskyy V, et al. Whole genome sequencing of *Mycobacterium tuberculosis* for detection of drug resistance: a systematic review. *ClinMicrobiol Infect*. 2017; 23: 61-68.
8. World Health Organization. 2015 Global Tuberculosis Report. Geneva: WHO; 2015.
9. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford AB, Marais BJ, et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. *J Antimicrob Chemother*. 2014; 70: 1198-1202.
10. Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. *Drug Discov Today*. 2008; 13:1090-1098.
11. Kapoor R, Eimerman PR, Hardy JW, Cirillo JD, Contag CH, Barron AE, et al. Efficacy of antimicrobial peptoids against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2011; 55: 3058-3062.
12. Charp PA, Rice WG, Raynor RL, Reimund E, Kinkade Jr JM, Ganz T, et al. Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils. *Biochem Pharmacol*. 1988; 37: 951-956.
13. Kalita A, Verma I, Khuller GK. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. *J Infect Dis*. 2004; 190: 1476-1480.
14. Corrales-Garcia L, Ortiz E, Castañeda-Delgado J, Rivas-Santiago B, Corzo G. Bacterial expression and antibiotic activities of recombinant variants of human β -defensins on pathogenic bacteria and *M. tuberculosis*. *Protein Expr Purif*. 2013; 89: 33-43.
15. Torres-Juarez F, Cardenas-Vargas A, Montoya-Rosales A, González-Curiel I, Garcia-Hernandez MH, Enciso-Moreno JA, et al. LL-37 immunomodulatory activity during *Mycobacterium tuberculosis* infection in macrophages. *Infect Immun*. 2015; 83: 4495-503.
16. Shin DM, Jo EK. Antimicrobial peptides in innate immunity against mycobacteria. *Immune Netw*. 2011; 11: 245-252.
17. Rivas-Santiago B, Santiago CE, Castañeda-Delgado JE, León-Contreras JC, Hancock RE, Hernandez-Pando R, et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against *Mycobacterium tuberculosis*. *Int J Antimicrob Agents*. 2013; 41: 143-148.
18. Michels K, Nemeth E, Ganz T, Mehrad B. Hecpudin and host defense against infectious diseases. *PLoSPathog*. 2015; 11: e1004998.
19. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP, et al. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. *J Leukoc Biol*. 2007; 82: 934-945.
20. Endsley JJ, Furrer JL, Endsley MA, McIntosh MA, Maue AC, Waters WR, et al. Characterization of bovine homologues of granulysin and NK-lysin. *J Immunol*. 2004; 173: 2607-2614.
21. Gutsmann T. Interaction between antimicrobial peptides and mycobacteria. *Biochim Biophys Acta*. 2016; 1858: 1034-1043.
22. Dieli F, Troye-Blomberg M, Ivanyi J, Fournié JJ, Krensky AM, Bonneville M, et al. Granulysin-dependent killing of intracellular and extracel-



- lular *Mycobacterium tuberculosis* by V γ 9/V δ 2 T lymphocytes. *J Infect Dis.* 2001; 184: 1082-1085.
23. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. *Nat Rev Immunol.* 2011; 11: 343-354.
24. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. Antimicrobial peptides present in mammalian skin and gut are multi-functional defence molecules. *Curr Pharm Des.* 2010; 16: 1024-1039.
25. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, et al. The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. *FASEB J.* 2003; 17: 776-778.
26. Abedinzadeh M, Gaeini M, Sardari S. Natural antimicrobial peptides against *Mycobacterium tuberculosis*. *J Antimicrob Chemother.* 2015; 70: 1285-1289.
27. Silva JP, Appelberg R, Gama FM. Antimicrobial peptides as novel anti-tuberculosis therapeutics. *Biotechnol Adv.* 2016; 34: 924-940.
28. Arranz-Trullén J, Lu L, Pulido D, Bhakta S, Boix E. Host antimicrobial peptides: The promise of new treatment strategies against tuberculosis. *Front Immunol.* 2017; 8: 1499.
29. Boro M, Singh V, Balaji KN. *Mycobacterium tuberculosis*-triggered Hippo pathway orchestrates CXCL1/2 expression to modulate host immune responses. *Sci Rep.* 2016; 6: 37695.
30. Cao X, Zhang Y, Mao R, Teng D, Wang X, Wang J, et al. Design and recombination expression of a novel plectasin-derived peptide MP1106 and its properties against *Staphylococcus aureus*. *Appl Microbiol Biotechnol.* 2015; 99: 2649-2662.
31. Maqueda M, Gálvez A, Bueno MM, Sanchez-Barrena MJ, González C, Albert A, et al. Peptide AS-48: prototype of a new class of cyclic bacteriocins. *Curr Protein Pept Sci.* 2004; 5: 399-416.
32. Tenland E, Krishnan N, Rönnholm A, Kalsum S, Puthia M, Mörgelin M, et al. A novel derivative of the fungal antimicrobial peptide plectasin is active against *Mycobacterium tuberculosis*. *Tuberculosis.* 2018; 113: 231-238.
33. Aguilar-Pérez C, Gracia B, Rodrigues L, Vitoria A, Cebrián R, Deboosère N, et al. Synergy between circular bacteriocin AS-48 and ethambutol against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2018; 62: e00359-18.
34. Asfaw H, Laqua K, Walkowska AM, Cunningham F, Martinez-Martinez MS, Cuevas-Zurita JC, et al. Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent. *Plos One.* 2017; 12: e0176088.
35. Khalil ZG, Salim AA, Lacey E, Blumenthal A, Capon RJ. Wollamides: Antimycobacterial cyclic hexapeptides from an Australian soil *Streptomyces*. *Org Lett.* 2014; 16: 5120-5123.
36. Tsutsumi LS, Tan GT, Sun D. Solid-phase synthesis of cyclic hexapeptides wollamides A, B and desotamide B. *Tetrahedron Lett.* 2017; 58: 2675-2680.
37. Jin HS, Lee HM, Lee DH, Cha GH, Cho KS, Jang J, et al. Functional characterisation of the *Drosophila* cg6568 gene in host defence against *Mycobacterium marinum*. *Microbes Infect.* 2017; 19: 351-357.